atai Life Sciences (ATAI) Competitors $4.58 -0.07 (-1.51%) Closing price 04:00 PM EasternExtended Trading$4.55 -0.03 (-0.66%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATAI vs. MENS, KYMR, SRRK, BHC, XENE, AMRX, HCM, NAMS, RARE, and MORShould you be buying atai Life Sciences stock or one of its competitors? The main competitors of atai Life Sciences include Jyong Biotech (MENS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Bausch Health Cos (BHC), Xenon Pharmaceuticals (XENE), AMNEAL PHARMACEUTICALS (AMRX), HUTCHMED (HCM), NewAmsterdam Pharma (NAMS), Ultragenyx Pharmaceutical (RARE), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. atai Life Sciences vs. Its Competitors Jyong Biotech Kymera Therapeutics Scholar Rock Bausch Health Cos Xenon Pharmaceuticals AMNEAL PHARMACEUTICALS HUTCHMED NewAmsterdam Pharma Ultragenyx Pharmaceutical MorphoSys Jyong Biotech (NASDAQ:MENS) and atai Life Sciences (NASDAQ:ATAI) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation. Do institutionals and insiders believe in MENS or ATAI? 28.4% of atai Life Sciences shares are owned by institutional investors. 26.8% of atai Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend MENS or ATAI? atai Life Sciences has a consensus price target of $11.25, indicating a potential upside of 145.63%. Given atai Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe atai Life Sciences is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00atai Life Sciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.17 Is MENS or ATAI more profitable? Jyong Biotech's return on equity of 0.00% beat atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Jyong BiotechN/A N/A N/A atai Life Sciences N/A -85.43%-64.38% Which has stronger valuation & earnings, MENS or ATAI? Jyong Biotech has higher earnings, but lower revenue than atai Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJyong BiotechN/AN/AN/AN/AN/Aatai Life Sciences$310K3,166.70-$149.27M-$0.69-6.64 Does the media favor MENS or ATAI? In the previous week, atai Life Sciences had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for atai Life Sciences and 2 mentions for Jyong Biotech. atai Life Sciences' average media sentiment score of 0.77 beat Jyong Biotech's score of 0.64 indicating that atai Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive atai Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summaryatai Life Sciences beats Jyong Biotech on 9 of the 11 factors compared between the two stocks. Get atai Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATAI vs. The Competition Export to ExcelMetricatai Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$981.68M$4.13B$5.76B$9.75BDividend YieldN/A1.26%3.95%4.02%P/E Ratio-6.6428.9231.4526.39Price / Sales3,166.70169.38431.57159.28Price / CashN/A27.1437.7559.42Price / Book6.842.9010.566.59Net Income-$149.27M$189.47M$3.27B$265.83M7 Day Performance0.22%-0.08%0.60%0.18%1 Month Performance38.37%16.53%5.42%2.13%1 Year Performance252.31%14.82%50.36%21.07% atai Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATAIatai Life Sciences3.4674 of 5 stars$4.58-1.5%$11.25+145.6%+269.0%$981.68M$310K-6.6480MENSJyong BiotechN/A$41.50-7.2%N/AN/A$3.16BN/A0.0031KYMRKymera Therapeutics3.0853 of 5 stars$43.62+2.3%$59.11+35.5%-14.0%$3.12B$47.07M-12.57170Positive NewsSRRKScholar Rock4.555 of 5 stars$31.52+0.4%$45.14+43.2%+268.1%$3.03B$33.19M-10.83140Positive NewsBHCBausch Health Cos4.3082 of 5 stars$8.02-3.8%$9.00+12.2%+21.5%$2.97B$9.63B30.8520,700XENEXenon Pharmaceuticals2.2883 of 5 stars$37.82-1.1%$53.20+40.7%-3.7%$2.92B$9.43M-10.65210Positive NewsAMRXAMNEAL PHARMACEUTICALS3.2104 of 5 stars$9.28-1.8%$11.60+25.0%+10.9%$2.91B$2.79B928.738,100Positive NewsInsider TradeHCMHUTCHMED2.4338 of 5 stars$16.43-0.1%$28.00+70.4%-14.3%$2.87B$630.20M0.001,811NAMSNewAmsterdam Pharma3.6213 of 5 stars$25.42+1.4%$41.20+62.1%+46.8%$2.86B$45.56M-15.694Insider TradeRAREUltragenyx Pharmaceutical4.6524 of 5 stars$29.70+0.0%$81.50+174.4%-47.6%$2.86B$560.23M-5.371,294MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies MENS Competitors KYMR Competitors SRRK Competitors BHC Competitors XENE Competitors AMRX Competitors HCM Competitors NAMS Competitors RARE Competitors MOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATAI) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding atai Life Sciences N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access